Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ENTO

Entero Therapeutics 8/14/2025 Earnings Report

Entero Therapeutics logo
$2.52 +0.01 (+0.40%)
As of 05/1/2026
ProfileEarnings HistoryForecast

Entero Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Entero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Entero Therapeutics Announcement Details

Quarter
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Entero Therapeutics' next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules.

Conference Call Resources

Entero Therapeutics Earnings Headlines

Entero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% - Should You Sell?
April 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30749512
GridAI Technologies Faces Default on Revolving Loan Agreement
April 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gridai-technologies-faces-default-on-revolving-loan-agreement?utm_source=marketbeat.com&utm_medium=referral
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 5 at 1:00 AM  |  American Alternative (Ad)
Entero Therapeutics Inc.
December 4, 2025  |  wsj.comhttps://www.wsj.com/market-data/quotes/us/ENTO
NASDAQ: ENTO’s Grid AI Strikes Texas Hyperscale Deal as its $50M Industrial Software Platform Enters the AI Race
November 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/nasdaq-ento-s-grid-ai-strikes-texas-hyperscale-deal-as-its-50m-industrial-software-platform-enters-the-ai-race/ar-AA1QKDxg
Entero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy
November 19, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/enteros-grid-ai-announces-major-103000589.html
See More Entero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email.

About Entero Therapeutics

Entero Therapeutics (NASDAQ:ENTO) (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations.

Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.

View Entero Therapeutics Profile
Earnings Tools